Portal de Periódicos da CAPES

Is The Victoria Trial Population Representative In Latin America? Analysis Of The Colombian Heart Failure Registry

2023; Elsevier BV; Volume: 29; Issue: 4 Linguagem: Inglês

10.1016/j.cardfail.2022.10.286

1532-8414

Juan Esteban Gómez‐Mesa, Alex Rivera-Toquica, Luis Eduardo Echeverría, Patricia Rodriguez Gomez, Fernando Rivera, Guillermo Trout Guardiola, Marco De Leon Espitia, Edgar Castro Osorio, Carlos Renteria Asprilla, Nelson Lopez Garzon, Armando Alcala Hernandez, Jose Accini Mendoza, Gary Baquero Lozano, Argemiro Martinez Carvajal, Paula Carolina Luna, Clara Saldarriaga,

Heart Failure Treatment and Management

Background The VICTORIA trial evaluated the effect of vericiguat in patients with heart failure (HF) and reduced ejection fraction with a recent worsening HF event (WHFE), observing a benefit in the risk of cardiovascular mortality and of HF hospitalization compared to placebo. The representativeness of the VICTORIA population in Latin America is unknown. Methods Patients with HF, ejection fraction <45%, and a WHFE enrolled in RECOLFACA (Registro Colombiano de Falla Cardiaca) during 2017-2019 were included. RECOLFACA enrolled adult patients with a HF diagnosis from 60 centers in Colombia. Characteristics and outcomes of patients in the RECOLFACA were compared to the VICTORIA population. Results OF the total 2528 patients included in the registry, 1890 (74.8%) had an ejection fraction <45% and a WHFE. The VICTORIA population was similar to RECOLFACA patients in mean age (67.3 vs 66.9), ejection fraction (28.9% vs 28.4%), the prevalence of COPD (17.1% vs 15.7%), and the median eGFR (61.5 vs 61.4 mL/min/1.73m2). On the other hand, RECOLFACA patients were more frequently women, with a lower prevalence of atrial fibrillation, diabetes mellitus, and coronary artery disease. The rate of HF hospitalization at 1 year was 29.6% in the placebo group of VICTORIA, compared to 26.9% in the RECOLFACA. Conclusions Patients enrolled in the RECOLFACA that meet the VICTORIA definition, had similar characteristics and outcomesas observed in the VICTORIA population. This is a population with unmet medical needs that need to be identified in our health care system. The VICTORIA trial evaluated the effect of vericiguat in patients with heart failure (HF) and reduced ejection fraction with a recent worsening HF event (WHFE), observing a benefit in the risk of cardiovascular mortality and of HF hospitalization compared to placebo. The representativeness of the VICTORIA population in Latin America is unknown. Patients with HF, ejection fraction <45%, and a WHFE enrolled in RECOLFACA (Registro Colombiano de Falla Cardiaca) during 2017-2019 were included. RECOLFACA enrolled adult patients with a HF diagnosis from 60 centers in Colombia. Characteristics and outcomes of patients in the RECOLFACA were compared to the VICTORIA population. OF the total 2528 patients included in the registry, 1890 (74.8%) had an ejection fraction <45% and a WHFE. The VICTORIA population was similar to RECOLFACA patients in mean age (67.3 vs 66.9), ejection fraction (28.9% vs 28.4%), the prevalence of COPD (17.1% vs 15.7%), and the median eGFR (61.5 vs 61.4 mL/min/1.73m2). On the other hand, RECOLFACA patients were more frequently women, with a lower prevalence of atrial fibrillation, diabetes mellitus, and coronary artery disease. The rate of HF hospitalization at 1 year was 29.6% in the placebo group of VICTORIA, compared to 26.9% in the RECOLFACA. Patients enrolled in the RECOLFACA that meet the VICTORIA definition, had similar characteristics and outcomesas observed in the VICTORIA population. This is a population with unmet medical needs that need to be identified in our health care system.